<DOC>
	<DOC>NCT01003431</DOC>
	<brief_summary>This study will evaluate the immunogenicity and safety of the pertussis component of DTwP (whole-cell pertussis containing vaccine) when administered concomitantly with RotaTeq™ or Rotatrix™.</brief_summary>
	<brief_title>A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)</brief_title>
	<detailed_description />
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infants History of abdominal disorders, intestinal folding, or abdominal surgery Impaired immune system Prior administration of any rotavirus vaccine or DTwP/DTaP Fever of &gt;= 38.1C (100.5F) at the time of vaccination History of prior rotavirus infection, chronic diarrhea, or failure to thrive Evidence of active gastrointestinal illness</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>